|
|
||||||||
Hölting T, Siperstein AE, Clark OH, Duh Q-Y. Epidermal growth factor (EGF)- and transforming growth factor alpha-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro. Eur J Endocrinol 1995;132:229–35. ISSN 0804–4643
We have shown recently that epidermal growth factor (EGF) enhanced invasion and growth of differentiated thyroid cancer cells in vitro and in vivo. The present study analyzed the effects of transforming growth factor alpha (TGF-
) on invasion and growth of a follicular thyroid cancer cell line (FTC133) and whether blocking the EGF receptor by a monoclonal antibody (Mab528) or blocking the tyrosine kinase of the receptor by genistein abolished the EGF- and TFG-
-mediated effects. Growth and invasion (penetration of 8-µm pore polycarbonate membranes coated with Matrigel) were determined by the dimethylthiazol-diphenyltetrazolium bromide assay. Epidermal growth factor (10 ng/l) stimulated invasion of FTC133 by 42% and TGF-
(10 ng/l) stimulated invasion of FTC133 by 27% (p < 0.02). Both growth factors also enhanced growth by 62% (EGF) and 30% (TGF-
) (p < 0.003). Epidermal growth factor receptor antibodies (1 µg/ml) abolished EGF-mediated stimulation of invasion and growth completely and that of TGF-
by 93%. At 100 ng/ml genistein reversed EGF and TGF-
stimulation, and at 1 µg/ml it inhibited invasion (27%) and growth (40%) of unstimulated FTC133 (p < 0.02). We conclude that TGF-
stimulates invasion and growth of follicular thyroid cancer by binding to the EGF receptors, that EGF- and TGF-
-mediated effects can be blocked by antagonism to the EGF receptor and to tyrosine kinase, and that genistein not only neutralized EGF and TGF-
effects but also inhibited invasion and growth of unstimulated FTC133. Therefore, tyrosine kinase activity via other signalling systems must be crucial for basal invasion and growth of follicular thyroid cancer cells in culture.
Thomas Hölting, Department of Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
This article has been cited by other articles:
![]() |
M. N. Younes, Y. D. Yazici, S. Kim, S. A. Jasser, A. K. El-Naggar, and J. N. Myers Dual Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor Inhibition with NVP-AEE788 for the Treatment of Aggressive Follicular Thyroid Cancer. Clin. Cancer Res., June 1, 2006; 12(11): 3425 - 3434. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. N. Younes, O. G. Yigitbasi, Y. W. Park, S.-J. Kim, S. A. Jasser, V. S. Hawthorne, Y. D. Yazici, M. Mandal, B. N. Bekele, C. D. Bucana, et al. Antivascular Therapy of Human Follicular Thyroid Cancer Experimental Bone Metastasis by Blockade of Epidermal Growth Factor Receptor and Vascular Growth Factor Receptor Phosphorylation Cancer Res., June 1, 2005; 65(11): 4716 - 4727. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Pyka, A. Glogowska, H. Dralle, C. Hoang-Vu, and T. Klonisch Cytoplasmic Domain of proEGF Affects Distribution and Post-Translational Modification of Microtubuli and Increases Microtubule-Associated Proteins 1b and 2 Production in Human Thyroid Carcinoma Cells Cancer Res., February 15, 2005; 65(4): 1343 - 1351. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ying, H. Suzuki, H. Furumoto, R. Walker, P. Meltzer, M. C. Willingham, and S.-Y. Cheng Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma Carcinogenesis, September 1, 2003; 24(9): 1467 - 1479. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-W. Park, M. W. Yeh, M. G. Wong, M. Lobo, W. C. Hyun, Q.-Y. Duh, and O. H. Clark The Heat Shock Protein 90-Binding Geldanamycin Inhibits Cancer Cell Proliferation, Down-Regulates Oncoproteins, and Inhibits Epidermal Growth Factor-Induced Invasion in Thyroid Cancer Cell Lines J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3346 - 3353. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Braga-Basaria and M. D. Ringel Beyond Radioiodine: A Review of Potential New Therapeutic Approaches for Thyroid Cancer J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1947 - 1960. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Steinert, M. Wobus, C. Boltze, A. Schutz, M. Wahlbuhl, J. Hamann, and G. Aust Expression and Regulation of CD97 in Colorectal Carcinoma Cell Lines and Tumor Tissues Am. J. Pathol., November 1, 2002; 161(5): 1657 - 1667. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Korem, M. B. Resnick, and Z. Kraiem Similar and Divergent Patterns in the Regulation of Matrix Metalloproteinase-1 (MMP-1) and Tissue Inhibitor of MMP-1 Gene Expression in Benign and Malignant Human Thyroid Cells J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3322 - 3327. [Abstract] [Full Text] |
||||
![]() |
M. Yebra, G. C.N. Parry, S. Stromblad, N. Mackman, S. Rosenberg, B. M. Mueller, and D. A. Cheresh Requirement of Receptor-bound Urokinase-type Plasminogen Activator for Integrin alpha vbeta 5-directed Cell Migration J. Biol. Chem., November 15, 1996; 271(46): 29393 - 29399. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |